Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272116 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL5856290 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL17760869 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL3272074 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL432514 | 0.93 | DUT (0.39) | DUT | |
| SCHEMBL8063404 | 0.88 | DUT (0.43) | DUT | |
| SCHEMBL9007756 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL27241092 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL14245094 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL25378318 | 0.85 | DUT (0.36) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066011-A1 | METHOD FOR PREPARING SITE-SPECIFICALLY MODIFIED PROTEIN BASED ON NOVEL CARBON-CARBON BOND FORMATION | PROMEDIGEN (KR) | 2018-03-08 | — | — | US | claimed |
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | GENZYME CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4583972-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Sionna Therapeutics Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-06-19 | — | — | US | disclosed |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2025-06-19 | — | — | US | disclosed |
| US-6077873-A | COMPOUNDS HAVING ESTROGENIC AND/OR PROGESTAGENIC PROPERTIES | AKZO NOBEL N.V. (NL) | 2000-06-20 | — | — | US | disclosed |
| US-6066650-A | USEFUL FOR LOWERING SERUM LIPIDS AND TREATING ATHEROSCLEROSIS AND RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-23 | — | — | US | disclosed |
| US-6034098-A | ATHEROSCLEROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-07 | — | — | US | disclosed |
| WO-1999025740-A1 | COMPOSITIONS PROVIDING IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS AND PROCESSES FOR IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS | FMC CORPORATION (US) | 1999-05-27 | — | — | WO | disclosed |
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0886637-A4 | — | — | 1998-12-30 | — | — | EP | disclosed |
| EP-0886637-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0869132-A1 | \"Steroid compounds having contraceptive and anti-osteoporosis activity\ | Akzo Nobel N.V. (NL) | 1998-10-07 | — | — | EP | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1996026205-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | DUT 60/4885 |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | DUT 997/4885 |
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | CFTR, ABCC3, ABCD3 | DUT 4761/4885 |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | DUT 4761/4885 |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | DUT 4757/4885 |
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | DUT 2389/4885 |
| US-20180066011-A1 | METHOD FOR PREPARING SITE-SPECIFICALLY MODIFIED PROTEIN BASED ON NOVEL CARBON-CARBON BOND FORMATION | PTMS, CHAMP1, STUB1 | DUT 2636/4885 |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | DUT 2389/4885 |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | DUT 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.